Indofarma Tbk (INAF) - Total Assets

Latest as of September 2025: Rp581.56 Billion IDR ≈ $34.08 Million USD

Based on the latest financial reports, Indofarma Tbk (INAF) holds total assets worth Rp581.56 Billion IDR (≈ $34.08 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See INAF book value for net asset value and shareholders' equity analysis.

Indofarma Tbk - Total Assets Trend (2000–2024)

This chart illustrates how Indofarma Tbk's total assets have evolved over time, based on quarterly financial data.

Indofarma Tbk - Asset Composition Analysis

Current Asset Composition (December 2024)

Indofarma Tbk's total assets of Rp581.56 Billion consist of 21.7% current assets and 78.3% non-current assets.

Asset Category	Amount (IDR)	% of Total Assets
Cash & Equivalents	Rp0.00	1.6%
Accounts Receivable	Rp46.92 Billion	7.6%
Inventory	Rp33.33 Billion	5.4%
Property, Plant & Equipment	Rp383.13 Billion	62.0%
Intangible Assets	Rp2.88 Billion	0.5%
Goodwill	Rp0.00	0.0%

Asset Composition Trend (2000–2024)

This chart illustrates how Indofarma Tbk's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Indofarma Tbk (INAF) total market value.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Indofarma Tbk's current assets represent 21.7% of total assets in 2024, an increase from 0.0% in 2000.
Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, down from 9.6% in 2000.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
Asset Diversification: The largest asset category is property, plant & equipment at 62.0% of total assets.

Indofarma Tbk Competitors by Total Assets

Key competitors of Indofarma Tbk based on total assets are shown below.

Company	Country	Total Assets
Daihan Pharmaceutical Co.Ltd KQ:023910	Korea	₩344.02 Billion
Aurobindo Pharma Limited NSE:AUROPHARMA	India	Rs525.46 Billion
China Resources Sanjiu Medical & Pharmaceutical Co Ltd SHE:000999	China	CN¥56.56 Billion
Ningbo Menovo Pharm Co Ltd SHG:603538	China	CN¥4.75 Billion
Zhejiang Xianju Pharmaceutical Co Ltd SHE:002332	China	CN¥7.26 Billion
Qianjiang Yongan Pharmaceutical Co Ltd SHE:002365	China	CN¥2.26 Billion
Zhejiang Cheng Yi Pharmaceutical Co Ltd SHG:603811	China	CN¥1.69 Billion
Hainan Honz Pharmaceutical Co SHE:300086	China	CN¥1.88 Billion

Indofarma Tbk - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.13	0.15	1.36
Quick Ratio	0.10	0.07	1.18
Cash Ratio	0.00	0.00	0.00
Working Capital	Rp-1.09 Trillion	Rp-1.21 Trillion	Rp297.98 Billion

Indofarma Tbk - Advanced Valuation Insights

This section examines the relationship between Indofarma Tbk's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	6.53
Latest Market Cap to Assets Ratio	0.00
Asset Growth Rate (YoY)	-18.6%
Total Assets	Rp618.16 Billion
Market Capitalization	$22.88 Million USD

Valuation Analysis

Below Book Valuation: The market values Indofarma Tbk's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Indofarma Tbk's assets decreased by 18.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Indofarma Tbk (2000–2024)

The table below shows the annual total assets of Indofarma Tbk from 2000 to 2024.

Year	Total Assets	Change
2024-12-31	Rp618.16 Billion ≈ $36.22 Million	-18.64%
2023-12-31	Rp759.83 Billion ≈ $44.52 Million	-50.47%
2022-12-31	Rp1.53 Trillion ≈ $89.89 Million	-23.75%
2021-12-31	Rp2.01 Trillion ≈ $117.89 Million	+17.42%
2020-12-31	Rp1.71 Trillion ≈ $100.39 Million	+23.80%
2019-12-31	Rp1.38 Trillion ≈ $81.09 Million	-4.05%
2018-12-31	Rp1.44 Trillion ≈ $84.52 Million	-5.72%
2017-12-31	Rp1.53 Trillion ≈ $89.64 Million	+10.73%
2016-12-31	Rp1.38 Trillion ≈ $80.96 Million	-9.92%
2015-12-31	Rp1.53 Trillion ≈ $89.87 Million	+22.86%
2014-12-31	Rp1.25 Trillion ≈ $73.15 Million	-3.57%
2013-12-31	Rp1.29 Trillion ≈ $75.85 Million	+8.91%
2012-12-31	Rp1.19 Trillion ≈ $69.65 Million	+6.61%
2011-12-31	Rp1.11 Trillion ≈ $65.33 Million	+51.90%
2010-12-31	Rp733.96 Billion ≈ $43.01 Million	+0.81%
2009-12-31	Rp728.03 Billion ≈ $42.66 Million	-24.62%
2008-12-31	Rp965.81 Billion ≈ $56.59 Million	-4.32%
2007-12-31	Rp1.01 Trillion ≈ $59.15 Million	+46.95%
2006-12-31	Rp686.94 Billion ≈ $40.25 Million	+32.40%
2005-12-31	Rp518.82 Billion ≈ $30.40 Million	-0.97%
2004-12-31	Rp523.92 Billion ≈ $30.70 Million	-17.62%
2003-12-31	Rp635.96 Billion ≈ $37.26 Million	-21.49%
2002-12-31	Rp810.03 Billion ≈ $47.46 Million	-0.20%
2001-12-31	Rp811.62 Billion ≈ $47.56 Million	+50.81%
2000-12-31	Rp538.17 Billion ≈ $31.53 Million	--

About Indofarma Tbk

JK:INAF Indonesia Drug Manufacturers - Specialty & Generic

Market Cap

$22.88 Million

Rp390.51 Billion IDR

Market Cap Rank

#24606 Global

#524 in Indonesia

Share Price

Rp126.00

Change (1 day)

+0.00%

52-Week Range

Rp126.00 - Rp126.00

All Time High

Rp6975.00